Colombian-Canadian cannabis firm Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), has announced the delivery of its first EU-GMP medical cannabis product to Germany. Working with German firm Nimbus Health, Khiron products have been stocked in the Nimbus warehouse and are ready to be prescribed to patients via a network of 300 German pharmacies.
This represents a new revenue stream for Khiron and positions its European team to execute on its German medical strategy. Leveraging Nimbus Health’s large distribution network and Khiron’s ongoing investments in physician education, the Canadian listed firm with Colombian operations will focus on indications such as anxiety, substance use disorder, and migraines, addressing patient needs and improving access to medical cannabis.
The launch product is Khiron’s 1/14 high-CBD flower, which will focus on indications such as anxiety, substance use disorder, and migraines, addressing patient needs and improving access to medical cannabis.
“Since signing our distribution agreement with Nimbus Health in 2020, the company’s European Sales and Marketing teams have been actively educating doctors and raising awareness for our products. We are excited to launch our portfolio with Khiron 1/14, a product that covers unmet medical need in the German market. As we continue to expand our presence in the UK and Germany, we will leverage our clinical expertise from Colombia to provide the EU market with additional cannabis-based medicinal products,” said Tejinder Virk, President of Khiron Europe.
Franziska Katterbach, Managing Director & Chief Legal Officer for Khiron Europe based in Frankfurt, commented, “I would like to thank our European team for their unwavering perseverance over the past few months; their efforts have allowed us to achieve this significant milestone despite the challenges of the global pandemic and Germany’s strict regulatory environment. With all permits in place and product now available for sale, we look forward to increasing our presence in this growing market with over 60,000 medical cannabis patients and a population of over 82 million people. We are already developing additional cannabis-based medicinal products from our certified strains recently imported from Colombia to improve access and product selection for German patients.”